BlueSphere Bio to Present Update and Join Panel at 2024 BIO Convention

BlueSphere Bio, a company specializing in the development of innovative T cell receptor (TCR)-based therapies, has announced significant participation in the upcoming 2024 BIO International Convention. This event will take place from June 3 to June 6, 2024, in San Diego, California. Keir Loiacono, Esq., the Chief Executive Officer of BlueSphere Bio, is slated to present a corporate update and engage in a panel discussion during the convention.

The corporate update will focus on BlueSphere’s advancements towards launching its first clinical program targeting high-risk leukemia. The highlight will be the clinical development of BSB-1001, BlueSphere’s premier TCR-based candidate identified through their advanced TCXpress™ platform. This candidate targets the minor histocompatibility antigen-1 (HA-1) and will be evaluated in conjunction with standard allogeneic stem cell transplant therapies in a first-in-human study.

BlueSphere Bio’s TCXpress™ platform is designed to streamline the identification and characterization of T cell receptors with remarkable efficiency. This platform not only supports the discovery of TCRs for use in TCR-based cell therapies but also facilitates the development of antibody-like molecules such as bi-specific T cell engagers. While BlueSphere Bio initially focuses on oncology, the TCXpress™ platform holds potential for applications in other therapeutic domains.

During the convention, BlueSphere Bio will also provide updates on additional clinical programs and their ongoing discovery efforts using the TCXpress™ platform. This platform’s capabilities are being leveraged to develop a diverse portfolio of TCR-based assets, with an initial focus on treating conditions like acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), and myeloid dysplastic syndrome (MDS).

As part of the TCX-101 program, BlueSphere Bio plans to administer its first dose of BSB-1001 to a patient in early 2025. This TCR T cell therapy is designed to target the minor histocompatibility antigen-1 (HA-1) and will be used alongside allogeneic hematopoietic stem cell transplants. The TCXpress™ platform is also instrumental in discovering TCRs that react against other clinically significant minor histocompatibility antigens (miHAs), potentially expanding the TCX-101 program.

In addition to the corporate update, Keir Loiacono will participate in a panel discussion moderated by Angus Liu, Senior Writer at Fierce Pharma and Fierce Biotech. The panel will explore the future of T cell-directed cancer therapies, addressing topics such as new applications for treating more patients, overcoming biological challenges in solid tumors, high relapse rates, manufacturing complexities, and costs.

Key details of BlueSphere Bio’s participation are as follows:

Corporate Update:
- Track: Cell and Gene Therapy and Genome Editing
- Date: Tuesday, June 4, 2024
- Time: 1:45 – 2:00 p.m. PT
- Location: San Diego Convention Center, Theater 4

Panel Discussion:
- Title: What’s Nex-T: Innovator Roundtable on T Cell Therapies in Oncology
- Date: Thursday, June 6, 2024
- Time: 9:00 a.m. – 10:00 a.m. PT
- Location: San Diego Convention Center, Room 24BC
- Moderator: Angus Liu, Senior Writer at Fierce Pharma and Fierce Biotech

BlueSphere Bio, established by UPMC Enterprises, operates as a stand-alone entity focused on translating scientific discoveries into clinical applications. The company leverages the proprietary TCXpress™ platform to expedite the discovery and functional characterization of TCRs, aiming to revolutionize the treatment landscape for various cancers and other diseases.

As BlueSphere Bio continues to develop its robust clinical pipeline, the forthcoming updates and discussions at the 2024 BIO International Convention are anticipated to offer valuable insights into the future trajectory of T cell-based therapies.